Melatonin osteoporosis prevention study (MOPS): A randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women

Journal of Pineal Research

Volumn 52, Issue 4, 2012, Pages 414-426

  Kotlarczyk, Mary P ^a   Lassila, Holly C ^a   O'Neil, Christine K ^a   D'Amico, Frank ^a   Enderby, Larry T ^b   Witt Enderby, Paula A ^a   Balk, Judith L ^c  

^a DUQUESNE UNIVERSITY   (United States)

^b Enderby Healthcare/Legal Consulting   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bone; melatonin; menopause specific quality of life intervention; osteoporosis; perimenopause; quality of life

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; LACTOSE; MELATONIN; OSTEOCALCIN; PLACEBO;

ADULT; ARTICLE; BEDTIME DOSAGE; BONE DENSITY; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MENOPAUSAL SYNDROME; MENSTRUAL CYCLE; OSSIFICATION; OSTEOLYSIS; PHYSICAL ACTIVITY; PITTSBURGH SLEEP QUALITY INDEX; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SLEEP PATTERN; WELLBEING;

ANALYSIS OF VARIANCE; BLOOD PRESSURE; BONE DENSITY; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDES; PERIMENOPAUSE; PLACEBOS; QUALITY OF LIFE; SLEEP;

EID: 84859726278     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00956.x     Document Type: Article

References (99)

1. Mansfield PK, Carey M, Anderson A, et al., Staging the menopausal transition: data from the TREMIN Research Program on Women's Health. Womens Health Issues 2004; 14: 220-226.
2. Avis NE, Colvin A, Bromberger JT, et al., Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: study of Women's Health Across the Nation. Menopause 2009; 16: 860-869.
3. Woods NF, Mitchell ES,. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 (Suppl 12B): 14-24.
4. Ebeling PR, Atley LM, Guthrie JR, et al., Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996; 81: 3366-3371.
5. Rosenbrock H, Seifert-Klauss V, Kaspar S, et al., Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med 2002; 40: 143-151.
6. Seifert-Klauss V, Prior JC,. Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010; 2010: 845180.
7. Prior JC,. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998; 19: 397-428.
8. Prior JC,. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 2005; 26: 297-300.
9. Santoro N, Brown JR, Adel T, et al., Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81: 1495-1501.
10. Zeitzer JM, Duffy JF, Lockley SW, et al., Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep 2007; 30: 1437-1443.
11. Lewy AJ, Wehr TA, Goodwin FK, et al., Light suppresses melatonin secretion in humans. Science 1980; 210: 1267-1269.
12. Iguichi H, Kato KI, Ibayashi H,. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-29.
13. Zhou JN, Liu RY, Van Heerikhuize J, et al., Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003; 34: 11-16.
14. Burgess HJ, Fogg LF,. Individual differences in the amount and timing of salivary melatonin secretion. PLoS ONE 2008; 3: e3055.
15. Machida M, Dubousset J, Imamura Y, et al., An experimental study in chickens for the pathogenesis of idiopathic scoliosis. Spine (Phila Pa 1976) 1993; 18: 1609-1615.
16. Turgut M, Kaplan S, Turgut AT, et al., Morphological, stereological and radiological changes in pinealectomized chicken cervical vertebrae. J Pineal Res 2005; 39: 392-399.
17. Machida M, Dubousset J, Imamura Y, et al., Role of melatonin deficiency in the development of scoliosis in pinealectomised chickens. J Bone Joint Surg Br 1995; 77: 134-138.
18. Machida M, Dubousset J, Yamada T, et al., Experimental scoliosis in melatonin-deficient C57BL/6J mice without pinealectomy. J Pineal Res 2006; 41: 1-7.
19. Tan DX, Manchester LC, Reiter RJ, et al., Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472: 206-214.
20. Conti A, Conconi S, Hertens E, et al., Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202.
21. Ostrowska Z, Kos-Kudla B, Marek B, et al., Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 2003; 37: 163-174.
22. Ostrowska Z, Kos-Kudla B, Nowak M, et al., The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul 2003; 37: 211-224.
23. Feskanich D, Hankinson SE, Schernhammer ES,. Nightshift work and fracture risk: the Nurses' Health Study. Osteoporos Int 2009; 20: 537-542.
24. Burch JB, Yost MG, Johnson W, et al., Melatonin, sleep, and shift work adaptation. J Occup Environ Med 2005; 47: 893-901.
25. Moreau A, Wang DS, Forget S, et al., Melatonin signaling dysfunction in adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2004; 29: 1772-1781.
26. Azeddine B, Letellier K, Wang da S, et al., Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic scoliosis. Clin Orthop Relat Res 2007; 462: 45-52.
27. Letellier K, Azeddine B, Parent S, et al., Estrogen cross-talk with the melatonin signaling pathway in human osteoblasts derived from adolescent idiopathic scoliosis patients. J Pineal Res 2008; 45: 383-393.
28. Brodner W, Krepler P, Nicolakis M, et al., Melatonin and adolescent idiopathic scoliosis. J Bone Joint Surg Br 2000; 82: 399-403.
29. Brzezinski A, Vangel MG, Wurtman RJ, et al., Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
30. Reiter RJ, Tan DX, Manchester LC, et al., Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007; 52: 11-28.
31. Reiter RJ,. The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1980; 1: 109-131.
32. Srinivasan V, Spence WD, Pandi-Perumal SR, et al., Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol 2009; 25: 779-785.
33. Vakkuri O, Kivela A, Leppaluoto J, et al., Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol 1996; 135: 188-192.
34. Bellipanni G, Bianchi P, Pierpaoli W, et al., Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001; 36: 297-310.
35. Diaz BL, Llaneza PC,. Endocrine regulation of the course of menopause by oral melatonin: first case report. Menopause 2008; 15: 388-392.
36. Cardinali DP, Ladizesky MG, Boggio V, et al., Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34: 81-87.
37. Witt-Enderby PA, Radio NM, Doctor JS, et al., Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006; 41: 297-305.
38. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, et al., Scientific basis for the potential use of melatonin in bone diseases: osteoporosis and adolescent idiopathic scoliosis. J Osteoporos 2010; 2010: 830231.
39. Witt-Enderby P, Clafshenkel WP, Kotlarczyk M, et al., Melatonin in bone health. In: Melatonin in the promotion of health., Watson RR, ed., CRC Press, Boca Raton, 2011; pp. 261-270.
40. Satomura K, Tobiume S, Tokuyama R, et al., Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 2007; 42: 231-239.
41. Ladizesky MG, Cutrera RA, Boggio V, et al., Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci 2001; 70: 557-565.
42. Ladizesky MG, Boggio V, Albornoz LE, et al., Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 2003; 34: 143-151.
43. Koyama H, Nakade O, Takada Y, et al., Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002; 17: 1219-1229.
44. Park KH, Kang JW, Lee EM, et al., Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res 2011; 51: 187-194.
45. Sowers MR, Greendale GA, Bondarenko I, et al., Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003; 14: 191-197.
46. Tremollieres FA, Strong DD, Baylink DJ, et al., Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh) 1992; 126: 329-337.
47. Scheven BA, Damen CA, Hamilton NJ, et al., Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro. Biochem Biophys Res Commun 1992; 186: 54-60.
48. Slootweg MC, Ederveen AG, Schot LP, et al., Oestrogen and progestogen synergistically stimulate human and rat osteoblast proliferation. J Endocrinol 1992; 133: R5-R8.
49. Simko F, Paulis L,. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42: 319-322.
50. Burgess HJ, Revell VL, Eastman CI,. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol 2008; 586: 639-647.
51. Lewis JE, Hilditch JR, Wong CJ,. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005; 50: 209-221.
52. Hilditch JR, Lewis J, Peter A, et al., A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996; 24: 161-175.
53. Buysse DJ, Reynolds CF 3rd, Monk TH, et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
54. Laakso ML, Lindblom N, Leinonen L, et al., Endogenous melatonin predicts efficacy of exogenous melatonin in consolidation of fragmented wrist-activity rhythm of adult patients with developmental brain disorders: a double-blind, placebo-controlled, crossover study. Sleep Med 2007; 8: 222-239.
55. Ruggiero SL, Mehrotra B,. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 2009; 60: 85-96.
56. Stepan JJ, Burr DB, Pavo I, et al., Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007; 41: 378-385.
57. Abrahamsen B, Eiken P, Eastell R,. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095-1102.
58. Shifren JL, Schiff I,. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010; 115: 839-855.
59. Gennari L, Merlotti D, Nuti R,. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging 2010; 5: 19-29.
60. Zhdanova IV, Wurtman RJ, Lynch HJ, et al., Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-558.
61. Wade A, Downie S,. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig Drugs 2008; 17: 1567-1572.
62. N ational O steoporosis F oundation. About Osteoporosis: Fast Facts. National Osteoporosis Foundation, Washington, DC, 2011.
63. Glover SJ, Eastell R, Mccloskey EV, et al., Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009; 45: 1053-1058.
64. Seifert-Klauss V, Mueller JE, Luppa P, et al., Bone metabolism during the perimenopausal transition: a prospective study. Maturitas 2002; 41: 23-33.
65. Vasikaran S, Eastell R, Bruyere O, et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22: 391-420.
66. Hannon R, Eastell R,. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11 (Suppl 6): S30-S44.
67. Manolagas SC,. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137.
68. Clarke B,. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008; 3 (Suppl 3): S131-S139.
69. Teitelbaum SL,. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427-435.
70. Kraus KH, Kirker-Head C,. Mesenchymal stem cells and bone regeneration. Vet Surg 2006; 35: 232-242.
71. Vaananen HK,. Mesenchymal stem cells. Ann Med 2005; 37: 469-479.
72. Kearns AE, Khosla S, Kostenuik PJ,. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155-192.
73. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
74. Nakade O, Koyama H, Ariji H, et al., Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 1999; 27: 106-110.
75. Roth JA, Kim BG, Lin WL, et al., Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999; 274: 22041-22047.
76. Radio NM, Doctor JS, Witt-Enderby PA,. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 2006; 40: 332-342.
77. Sethi S, Radio NM, Kotlarczyk MP, et al., Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 2010; 49: 222-238.
78. Man GC, Wong JH, Wang WW, et al., Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis. J Pineal Res 2011; 50: 395-402.
79. Okatani Y, Watanabe K, Morioka N, et al., Nocturnal changes in pineal melatonin synthesis during puberty: relation to estrogen and progesterone levels in female rats. J Pineal Res 1997; 22: 33-41.
80. Okatani Y, Morioka N, Wakatsuki A,. Changes in nocturnal melatonin secretion in perimenopausal women: correlation with endogenous estrogen concentrations. J Pineal Res 2000; 28: 111-118.
81. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al., Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38: 217-222.
82. Okatani Y, Morioka N, Hayashi K,. Changes in nocturnal pineal melatonin synthesis during the perimenopausal period: relation to estrogen levels in female rats. J Pineal Res 1999; 27: 65-72.
83. Sun L, Peng Y, Sharrow AC, et al., FSH directly regulates bone mass. Cell 2006; 125: 247-260.
84. Webley GE, Luck MR,. Melatonin directly stimulates the secretion of progesterone by human and bovine granulosa cells in vitro. J Reprod Fertil 1986; 78: 711-717.
85. Woo MM, Tai CJ, Kang SK, et al., Direct action of melatonin in human granulosa-luteal cells. J Clin Endocrinol Metab 2001; 86: 4789-4797.
86. Macphee AA, Cole FE, Rice BF,. The effect of melatonin on steroidogenesis by the human ovary in vitro. J Clin Endocrinol Metab 1975; 40: 688-696.
87. Webley GE, Leidenberger F,. The circadian pattern of melatonin and its positive relationship with progesterone in women. J Clin Endocrinol Metab 1986; 63: 323-328.
88. Bellipanni G, Dim F, Blasi F, et al., Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N Y Acad Sci 2005; 1057: 393-402.
89. Tamura H, Nakamura Y, Terron MP, et al., Melatonin and pregnancy in the human. Reprod Toxicol 2008; 25: 291-303.
90. Reiter RJ, Tan DX, Manchester LC, et al., Melatonin and reproduction revisited. Biol Reprod 2009; 81: 445-456.
91. Taketani T, Tamura H, Takasaki A, et al., Protective role of melatonin in progesterone production by human luteal cells. J Pineal Res 2011; 51: 207-213.
92. Ronnberg L, Kauppila A, Leppaluoto J, et al., Circadian and seasonal variation in human preovulatory follicular fluid melatonin concentration. J Clin Endocrinol Metab 1990; 71: 492-496.
93. Brzezinski A, Seibel MM, Lynch HJ, et al., Melatonin in human preovulatory follicular fluid. J Clin Endocrinol Metab 1987; 64: 865-867.
94. Tamura H, Nakamura Y, Korkmaz A, et al., Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 2009; 92: 328-343.
95. Niles LP, Wang J, Shen L, et al., Melatonin receptor mRNA expression in human granulosa cells. Mol Cell Endocrinol 1999; 156: 107-110.
96. Yie SM, Niles LP, Younglai EV,. Melatonin receptors on human granulosa cell membranes. J Clin Endocrinol Metab 1995; 80: 1747-1749.
97. Cagnacci A, Cannoletta M, Renzi A, et al., Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens 2005; 18: 1614-1618.
98. Doolen S, Krause DN, Dubocovich ML, et al., Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 1998; 345: 67-69.
99. Doolen S, Krause DN, Duckles SP,. Estradiol modulates vascular response to melatonin in rat caudal artery. Am J Physiol 1999; 276: H1281-H1288.